BioLineRx Ltd. (BLRX)
Develops cancer and rare disease treatments, including oral drugs and injectable therapies in clinical trials.
$2.81-0.00%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-27.4%
The outlook
BLRX is trading near its 52-week lows, well below both its 50- and 200-day moving averages. Analyst coverage leans bearish overall, though the average price target sits significantly above the current price. The stock remains in a downtrend with limited near-term momentum.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range27% of the way from its 52-week low to high
Price targetAvg target +523% vs current price
Analyst price target
~12-month · 2 analysts$17.50average target+522.8% vs now
Now $2.81
Low $12.00High $23.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$12.6M
52-wk high
$4.56
52-wk low
$2.15
50-day avg
$3.12
200-day avg
$3.03
Trailing P/E
—